104
Participants
Start Date
April 30, 2006
Primary Completion Date
November 30, 2013
Study Completion Date
November 30, 2013
RAF265
A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.
Novartis Investigative Site, Zurich
University of Pittsburgh Cancer Institute Dept of Hillman Cancer Center, Pittsburgh
University of Pennsylvania Health System Dept of Hospital of UnivofPenn, Philadelphia
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Medical Oncology, Baltimore
Georgia Regents University Cancer Clinical Research Unit, Augusta
Vanderbilt University Medical Center Dept. of Cancer Center, Nashville
University of Colorado Univ.ofColoradoCancerCenter, Aurora
Massachusetts General Hospital Dept of Cancer for Melanoma, Boston
Dana Farber Cancer Institute DFCI, Boston
Beth Israel Deaconess Medical Center Dept.ofBethIsraelDeaconess(3), Boston
University of Texas/MD Anderson Cancer Center Onc. Dept,, Houston
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY